The Depository Trust & Clearing Corporation (DTCC), the premier market infrastructure for the global financial services industry, today announced the appointment of Jennifer Peve as Head of Strategy and Business Development. In this new role, Peve will have overarching responsibility for the firm’s global corporate strategy, digital product development and strategic partnerships and alliances, reporting to DTCC President & CEO Michael Bodson. Peve will also join the DTCC Management Committee. This appointment is effective July 2, 2021.

At a time when the speed and breadth of technology advancement, especially in digital innovation, continues to accelerate and drive industry-wide change, Peve will be charged with maintaining strategic alignment across DTCC and ensuring coordination and adaptability in the formulation and execution of the firm’s strategy. She will also bring increased focus on leveraging new technologies to enhance the post-trade environment and position DTCC as the bridge between legacy and emerging technologies, building on successful initiatives she has led, including Project Ion (DTCC’s future vision of an alternative digital settlement service) and Project Whitney (DTCC’s digital product offering for private securities).

“Jennifer is a proven leader who has the unique ability to understand, conceptualize and shape the future of the post-trade environment as well as the application of new and emerging technologies to drive the creation of creative and effective products and solutions for our clients,” Bodson said. “Jennifer will bring together our corporate strategy, digital product development and strategic partnerships and alliances as we continue to make significant advances in transforming the post-trade environment and introducing and utilizing new technologies to drive down costs and risks for our clients.”

Peve joined DTCC in 2015 as Executive Director, Business Development and Fintech Strategy Office. She was promoted to Managing Director in 2018 and assumed expanded responsibilities for Global Partners and Innovation. She previously served as Executive Director, OTC Product Management, at CME Group.